Retrospective Analysis Across Six CheckMate Trials Reinforces Benefit of Nivolumab Plus Ipilimumab
Source: Doc Wire News, November 2024
A pooled analysis of six CheckMate studies in immune checkpoint inhibitor (ICI), specifically treatment with nivolumab plus ipilimumab (NIVO + IPI) versus NIVO monotherapy, aimed to describe the long-term overall survival in patients with ICI treatment-naïve unresectable/metastatic melanoma.
The studies for ICI-naïve unresectable/metastatic melanoma included CheckMate 003, 004, 066, 067, 069, and 511.
A study led by Georgina V. Long, PhD, MBBS, FRACP, and published in the Journal of Clinical Oncology analyzed data from 1,375 patients; 369 of 839 (44%) received NIVO + IPI and 168 of 536 (31%) patients received NIVO remained in follow-up. Nine (1%) and 22 (4%) patients, respectively, were still receiving treatment.